Trachoma Decline and Widespread Use of Antimicrobial Drugs
Jaya D. Chidambaram*, Mariko Bird*, Vivian Schiedler*, Alicia M. Fry†, Travis Porco‡, Ramesh C. Bhatta§, Hem Jha§, J.S.P. Chaudary§, Bruce Gaynor*, Elizabeth Yi*, John P. Whitcher*, Susie Osaki-Holm*, and Thomas M. Lietman*
Author affiliations: *University of California, San Francisco, California, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ‡California Department of Health Services, Berkeley, California, USA; §Geta Eye Hospital, Geta, Nepal
Figure 1. Antimicrobial drug use in Geta, Nepal. Antimicrobial drug sales in a 3-month period (mid-February to mid-May 2000) from all pharmacies in the Geta subdistrict, expressed as defined daily doses (DDDs) and as a percentage of the total DDDs sold (6). The shaded region represents antimicrobial drugs that are effective against Chylmydia trachomatis.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.